Feature | ACC | February 10, 2022 | By Melinda Taschetta-Millane

ACC 2022 Late-breaking Clinical Trials Announced

The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announced for the 2022 American College of Cardiology (ACC) meeting.

Getty Images

The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announced for the 2022 American College of Cardiology (ACC) meeting. Top experts will debate and discuss the outcomes of leading-edge trials at ACC.22 and explain how it all fits into current cardiology practice. There are five late-breaking clinical trial sessions, three featured clinical research sessions, and two late-breaking clinical trials (LBCT) deep dive sessions to help cardiologists stay up-to-date on the newest clinical research.

Search the sessions at virtual ACC.22 meeting at https://accscientificsession.acc.org/Plan-Your-Program/Education-Sessions


Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials

Saturday, April 2, 9:30 – 10:30 a.m. ET

VALOR-HCM: Mavacamten as An Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

SODIUM-HF: Study of Dietary Intervention Under 100 Mmol in Heart Failure

The POISE-3 Trial: Efficacy and Safety of Tranexamic Acid in Patients Undergoing Noncardiac Surgery

CHAP Trial: Antihypertensive Therapy For Mild Chronic Hypertension Improves Pregnancy Outcomes: A Pragmatic Multicenter RCT


ACC Featured Clinical Research I

Saturday, April 2, 11 a.m. – 12:15 p.m. ET

SCORED Trial: Sotagliflozin Significantly Reduces Cardiovascular Death, Myocardial Infarction, and Stroke in the Scored Trial

Bentracimab Immediately and Significantly Reverses the Antiplatelet Effects of Ticagrelor in Older People

COMPLETE: Effects of Complete Revascularization on Angina-related Quality of Life in Patients With St-segment Elevation Myocardial Infarction

The FAME 3 Trial: Quality of Life After Fractional Flow Reserve-guided Stenting Compared With Coronary Bypass Surgery

Results of the EDIT-CMD Randomized Clinical Trial: Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in Angina and Nonobstructive Coronary Arteries


Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials

Sunday, April 3, 8 – 9:15 a.m. ET

MITIGATE: A Pragmatic Randomized Trial of Icosapent Ethyl for High Cardiovascular Risk Adults in an Era of Coronavirus Disease 2019

TRANSLATE-TIMI 70: Effect of Vupanorsen on Non-high-density Lipoprotein Cholesterol Levels In Statin-treated Patients With Elevated Cholesterol

PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients With Acute Myocardial Infarction: A Double-blind, Placebo-controlled, Randomized Trial

APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial

SuperWIN: A Multisite, Randomized, Controlled Trial of a Supermarket and Web-based Intervention Targeting Nutrition For Cardiovascular Risk Reduction


Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials

Sunday, April 3, 9:45 – 11 a.m. ET

IVVE: Randomized Controlled Trial of Influenza Vaccine in Patients With Heart Failure to Reduce Adverse Vascular Events

METEORIC-HF: The Effect of Omecamtiv Mecarbil on Exercise Tolerance in Patients With Chronic Heart Failure and Reduced Ejection Fraction

PROMPT-HF: A Cluster-Randomized PRagmatic Trial Aimed at ImprOving Use of Guideline Directed Medical Therapy in OutPatienTs With Heart Failure

DIAMOND Trial: Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications For Heart Failure With Reduced Ejection Fraction

Updated Cumulative Results of Treatment With Mavacamten From the EXPLORER-LTE Cohort of the MAVA-LTE Study in Patients With Obstructive Hypertrophic Cardiomyopathy


Featured Clinical Research II

Sunday, April 3, 12:15 – 1:30 p.m. ET

PACIFIC AF: Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study Comparing the Safety of the Oral FXIa Inhibitor Asundexian With Apixaban in Patients With Atrial Fibrillation

Residual Leaks Post Left Atrial Appendage Occlusion

A Report From the mAFA-II Trial Long-term Extension Cohort: Consumer-led Screening For Atrial Fibrillation

Results From the PARTITA Trial: Catheter Ablation of Ventricular Tachycardia After the First Implantable Cardioverter Shock

Low Rates of Guideline Directed Care Associated With Higher Mortality in Patients With Infections of Pacemakers and Implantable Cardioverter Defibrillators


Late-Breaking Clinical Trials Deep Dive I

Sunday, April 3, 2 – 3:15 p.m. ET

Get even more insights from key clinical trials presented at ACC.22 and find out what it all means for your patients.


Late-Breaking Clinical Trials IV

Monday, April 4, 8:30 – 9:45 a.m. ET

The PROTECT Trial: Very Mild Perioperative Hypothermia Versus Aggressive Warming and Myocardial Injury After Non-cardiac Surgery

POISE-3: The Effects of a Hypotension-avoidance Strategy Versus a Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery

One-year Results of the Clasp TR Study: Transcatheter Treatment of Tricuspid Regurgitation

Insights From the Corevalve US Pivotal and SURTAVI Trials: Five-year Incidence, Timing and Predictors of Hemodynamic Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses

A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement


Late-Breaking Clinical Trials V

Monday, April 4, 11 a.m. – 12:15 p.m. ET

GHATI: Improving STEMI Management Internationally: Two-year Report of 4,015 Patients Enrolled in the American College of Cardiology - Global Heart Attack Treatment Initiative

The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis

GIPS-IV: The Groningen Intervention Study For the Preservation of Cardiac Function With Sodium Thiosulfate After St-segment Elevation Myocardial Infarction

BIO|GUARD-MI: The Clinical Effect of Arrhythmia Monitoring After Myocardial Infarction


Featured Clinical Research III

Monday, April 4, 12:45 – 2 p.m. ET

3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications

Fidelity Analyses: Finerenone and Cardiorenal Outcomes by History of Cardiovascular Disease in Patients With Type 2 Diabetes

Secondary Analysis of the CANTOS Trial: Differential Impact of Residual Inflammatory Risk and Residual Cholesterol Risk Among Atherosclerosis Patients With and Without Chronic Kidney Disease

Trends and Final Results of the North American Covid-19 Myocardial Infarction (NACMI) Registry

Results From the EMPULSE Trial: Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized For Acute Heart Failure


Late-Breaking Clinical Trials Deep Dive II

Monday, April 4, 2:30 – 3:45 p.m. ET

Get even more insights from key clinical trials presented at ACC.22 and find out what it all means for your patients.


Keynote Speakers Announced for ACC 2022

Find more news from ACC

Related Content

Feature | ACC | By Melinda Taschetta-Millane

Late-breaking clinical trials for the American College of Cardiology’s Annual Scientific Session Together with World ...

Home December 20, 2022
News | ACC

Nov. 4, 2022 — The American College of Cardiology and the American Heart Association have published a new guideline on ...

Home November 05, 2022
News | ACC

July 15, 2022 — The ACC has named Melvin R. Echols, MD, FACC, as its new Chief Diversity, Equity and Inclusion Officer ...

Home July 15, 2022
Feature | ACC | By Melinda Taschetta-Millane

In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) ...

Home May 11, 2022
News | ACC

April 12, 2022 – The American College of Cardiology (ACC) is establishing a new award in honor of Valentin Fuster, MD ...

Home April 12, 2022
News | ACC
April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...
Home April 04, 2022
News | ACC

April 3, 2022 — egnite, Inc., an advanced technology digital health company focused on providing artificial intelligence ...

Home April 03, 2022
News | ACC

April 3, 2022 — A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath ...

Home April 03, 2022
News | ACC

April 1, 2022 — Royal Philips, a global leader in health technology, announced new additions to its innovative ...

Home April 01, 2022
News | ACC
March 31, 2022 – Healthcare AI solutions provider Aidoc will be delivering a live demonstration of its comprehensive AI ...
Home March 31, 2022
Subscribe Now